Publications by authors named "Enrica Intini"

Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.

View Article and Find Full Text PDF

Multidrug-resistant tuberculosis continues to be a public health crisis. Urgent action is required to improve the coverage and quality of diagnosis, treatment and care for people affected by drug-resistant tuberculosis. To implement tuberculosis control, in 2018, WHO recommended cycloserine as one of the Group B drugs.

View Article and Find Full Text PDF

: To describe the phenotypic and genotypic features of two unrelated Italian amyotrophic lateral sclerosis (ALS) patients, a FALS case and an apparently sporadic case, carrying the same D124G SOD1 mutation. Since this mutation is very rare, previously reported in only one patient of unknown geographical origin, to look for a founder effect. : Cases were classified based on the El Escorial revised criteria.

View Article and Find Full Text PDF

IPF is a specific form of chronic fibrosing interstitial pneumonia of unknown cause, characterized by progressive worsening in lung function and an unfavorable prognosis. Current concepts on IPF pathogenesis are based on a dysregulated wound healing response, leading to an over production of extracellular matrix. Based on recent research however, several other mechanisms are now proposed as potential targets for novel therapeutic strategies.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Enrica Intini"

  • - Enrica Intini's research primarily focuses on the intersection of infectious diseases and pulmonary conditions, particularly exploring the implications of treatments and disease mechanisms related to tuberculosis and pulmonary thromboembolism.
  • - Notable findings include a detailed review of Clofazimine's potential in treating a spectrum of mycobacterial infections and the recognition of neuropsychiatric reactions related to cycloserine in multidrug-resistant tuberculosis therapy.
  • - Intini also investigates the genetic underpinnings of conditions like amyotrophic lateral sclerosis (ALS), aiming to establish genotype-phenotype correlations and potential common ancestries among affected individuals.